Radiographic, pathologic and molecular response characteristics
| Patient number | Radiographic response* | Residual tumor (%) | Pre-treatment PD-L1 (%) | Normalized tumor mutation burden | Driver genes with sequence alterations |
| 1 | PD | 100 | 0 | 344 | KRAS, STK11 |
| 2 | PD† | N/A | 1 | 109 | KRAS, KEAP1, STK11 |
| 3 | SD | 90 | 10 | 147 | KRAS, STK11, TP53 |
| 4 | PD | N/A | 1 | 63 | KRAS, KEAP1, STK11 |
| 5 | PR | 0 (pCR) | 75 | 554 | KRAS, STK11 |
| 6 | SD | 0 (pCR) | 95 | Undeterminable‡ | Undeterminable‡ |
| 7 | SD | 70 | 0 | 914 | TP53 |
| 8 | PD | N/A | 0 | 78 | BRAF, STK11, TP53 |
| 9 | SD | 20 | 30 | 99 | TP53 |
*All radiographic RECIST assessments were unconfirmed, as only one post-neoadjuvant treatment imaging assessment was made prior to surgical resection.
†Clear metastatic disease on PET imaging despite stable disease on RECIST response assessment of chest CT and thus coded as having “PD”.
‡Pre-treatment tumor tissue for patient 6 was insufficient for whole exome sequencing and thus genomic assessments could not be performed.
N/A, not applicable; pCR, pathologic complete response; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease.